| Date | Title | Description | |
|---|---|---|---|
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
| 26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
| 24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 20 Oct 2020 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 15 Oct 2020 | Announcement of general shareholders’ meeting | In view of the exceptional circumstances derived from the spread of Covid-19, the Company has agreed that the Ordinary General Meeting be held by exclusively telematic means. | Download |
| 01 Oct 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2020 | Download |
| 11 Sep 2020 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2020 General Shareholders Meeting. | Download |
| 27 Jul 2020 | On business and financial situation | The company releases the press release related to the 2020 first half financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |